Douglas Kwon
About Douglas Kwon
Douglas Kwon serves as the Chief Scientific Officer at Day Zero Diagnostics, Inc. and has a prominent background in infectious disease research, holding positions at Massachusetts General Hospital and Harvard Medical School.
Current Role at Day Zero Diagnostics
Douglas Kwon serves as the Chief Scientific Officer at Day Zero Diagnostics, Inc. since 2022. In this role, he oversees the scientific direction of the company, focusing on the development of innovative diagnostic solutions. His leadership is pivotal in advancing the company's mission to enhance pathogen detection and improve patient outcomes.
Work at Massachusetts General Hospital
Kwon has been an Associate Physician at Massachusetts General Hospital since 2017. His responsibilities include patient care and collaboration with other healthcare professionals. He previously held positions at the hospital, including Assistant Physician from 2013 to 2017 and Assistant in Medicine in the Infectious Disease Unit from 2012 to 2013.
Academic Contributions at Harvard Medical School
Douglas Kwon has held multiple academic positions at Harvard Medical School. He has been an Associate Professor of Medicine since 2018 and previously served as an Instructor of Medicine from 2009 to 2012. His teaching and research focus on infectious diseases, particularly HIV.
Educational Background and Training
Kwon's educational journey includes a Bachelor of Arts in Biochemistry and Molecular Biology from Harvard University, an M.D. Ph.D. in Microbiology and Immunology from New York University, and an Infectious Disease Fellowship at Massachusetts General Hospital and Brigham and Women's Hospital. He also completed his Internal Medicine Residency at Joan & Sanford I. Weill Medical College of Cornell University.
Research Focus and Collaborations
Kwon's research includes studying the mechanisms by which HIV affects mucosal immune responses, particularly in the lung, which increases susceptibility to tuberculosis. He collaborates with researchers in South Africa to address the HIV epidemic in developing countries and employs advanced techniques like next-generation sequencing to enhance understanding of immune responses.